Krebs Biochemicals Q3 FY26: Net Loss Widens to ₹312.65 Lakhs
Krebs Biochemicals reported unaudited results for Q3 FY26. The company posted a net loss of ₹312.65 lakhs for the quarter ended December 31, 2025, compared to a loss of ₹614.28 lakhs in the prior quarter. Loss per share for the quarter was ₹1.45. The Vizag manufacturing unit remains closed.
The announcement details financial results which directly affect investor perception and company valuation. The continued closure of the manufacturing unit also presents ongoing operational challenges.
The company reported a widening net loss for the quarter and nine months ended December 31, 2025, indicating a negative financial performance.
Krebs Biochemicals and Industries Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company's Board of Directors approved these results during a meeting held on February 9, 2026, which commenced at 12:00 Noon and concluded at 01:30 p.m.
For the third quarter ended December 31, 2025, the company reported a total income of ₹727.85 lakhs and total expenses of ₹1,040.49 lakhs, resulting in a loss before exceptional items and tax of ₹312.65 lakhs. This compares to a loss of ₹614.28 lakhs in the previous quarter (ended September 30, 2025) and a loss of ₹773.89 lakhs in the same quarter of the previous year (ended December 31, 2024).
For the nine months ended December 31, 2025, the total income stood at ₹1,694.52 lakhs, with total expenses amounting to ₹3,153.87 lakhs, leading to a loss before exceptional items and tax of ₹1,459.35 lakhs. The company reported a loss per share (basic and diluted) of ₹1.45 for the quarter and ₹6.77 for the nine-month period.
The company also provided an unaudited statement of assets and liabilities as of December 31, 2025. Total assets were ₹16,591.40 lakhs, while total equity was negative at ₹16,083.25 lakhs. Non-current liabilities stood at ₹21,513.35 lakhs, with current liabilities at ₹11,161.30 lakhs. The company's manufacturing unit in Vizag continued to be closed pursuant to an order from the Andhra Pradesh Pollution Control Board dated February 7, 2025.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.